Atacicept

• UNSPSC Description:

  Atacicept (TACI-Ig) is a is a recombinant fusion protein containing the extracellular, ligand-binding portion of the TACI receptor and the Fc portion of human IgG. Atacicept inhibits B cell stimulation by binding to B lymphocyte stimulator and a proliferation-inducing ligand. Atacicept can be used in research of B-cell autoimmune disease[1][2].

• Target Antigen:

  Others

• Type:

  Inhibitory Antibodies

• Related Pathways:

  Others

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/atacicept.html

• Purity:

  99.5

• Solubility:

  10 mM in DMSO

• Smiles:

  [Atacicept]

• References & Citations:

  [1]Gross JA, et, al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. Immunity. 2001 Aug;15(2):289-302. |[2]Gross JA, et, al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature. 2000 Apr 27;404(6781):995-9.

• Shipping Conditions:

  Dry Ice

• Storage Conditions:

  Store at -80°C for 2 years

• Clinical Information:

  Phase 3

• CAS Number:

  845264-92-8